Ad
related to: octreotide for carcinoid tumor removal surgery recovery time blurry vision
Search results
Results From The WOW.Com Content Network
An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide , a drug similar to somatostatin , is radiolabeled with indium-111 , [ 1 ] and is injected into a vein and travels through the bloodstream.
Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid-stimulating hormone (thyrotropinoma), [citation needed] diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors ().
Enrolled participants had tumors which could not be surgically removed and were worsening while receiving treatment with octreotide. [ 15 ] Participants were randomly assigned to receive either 177 Lu dotatate with long-acting octreotide or long-acting octreotide, at a higher dose, alone.
Enterochromaffin cells, which give rise to carcinoid tumors, were identified in 1897 by Nikolai Kulchitsky and their secretion of serotonin was established in 1953 [105] when the "flushing" effect of serotonin had become clinically recognized. Carcinoid heart disease was identified in 1952, and carcinoid fibrosis in 1961. [105]
A large fraction of cases are diagnosed after routine surgery for bowel obstruction. [4] Others may be diagnosed incidentally, or after investigation for carcinoid syndrome. The tumor typically produces serotonin, Tachykinin peptides and other substances, which cause flushing, tachycardia, diarrhea and in some cases fibrosis of the heart valves.
NEW YORK (Reuters) -Donald Trump may seek dismissal of the criminal case in which he was convicted in May of 34 felony counts involving hush money paid to a porn star, a judge ruled on Friday ...
Weight loss of 25%, Moreno and Grunvald noted, would reach results obtained by bariatric surgery. And in Novo Nordisk’s CagriSema trial, 40% of participants did lose at least 25% of their body ...
Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary to neuroendocrine tumors (formerly known as carcinoid tumors). [1] The syndrome is caused by neuroendocrine tumors most often found in the gut releasing biologically active substances into the blood causing symptoms such as flushing and diarrhea, and less frequently, heart failure, vomiting ...